Cardiovascular toxicity of tyrosine kinase inhibitors

Elie Mouhayar, Jean Bernard Durand, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Introduction: Small-molecule tyrosine kinase inhibitors (TKIs) have revolutionized the management of many malignancies. However, they also have been shown to be associated with a certain degree of cardiovascular side effects that are often reversible. Areas covered: As the number of new TKIs continues to grow, it is expected that clinicians will be facing the challenge of early detection and 10 management of these side effects while balancing the risk-benefit ratios of continuing with life-saving cancer therapy medications. This review will present the current knowledge related to incidence and proposed mechanisms of cardiovascular side effects of TKIs and also discuss treatment recommendations when available Expert opinion: We will present and discuss available data and suggest recommendations related to patient monitoring and early identification of TKIs related cardiovascular toxities.

Original languageEnglish (US)
Pages (from-to)687-696
Number of pages10
JournalExpert Opinion on Drug Safety
Volume12
Issue number5
DOIs
StatePublished - Sep 1 2013
Externally publishedYes

Fingerprint

Protein-Tyrosine Kinases
Expert Testimony
Physiologic Monitoring
Neoplasms
Odds Ratio
Incidence
Therapeutics

Keywords

  • Biomarkers
  • Cardiomyopathy
  • Cardiovascular toxicity
  • Hypertension
  • Thrombosis
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Cardiovascular toxicity of tyrosine kinase inhibitors. / Mouhayar, Elie; Durand, Jean Bernard; Cortes, Jorge.

In: Expert Opinion on Drug Safety, Vol. 12, No. 5, 01.09.2013, p. 687-696.

Research output: Contribution to journalReview article

Mouhayar, Elie ; Durand, Jean Bernard ; Cortes, Jorge. / Cardiovascular toxicity of tyrosine kinase inhibitors. In: Expert Opinion on Drug Safety. 2013 ; Vol. 12, No. 5. pp. 687-696.
@article{2ebdbc8a7e3147d486c4e4bc70d8b5c3,
title = "Cardiovascular toxicity of tyrosine kinase inhibitors",
abstract = "Introduction: Small-molecule tyrosine kinase inhibitors (TKIs) have revolutionized the management of many malignancies. However, they also have been shown to be associated with a certain degree of cardiovascular side effects that are often reversible. Areas covered: As the number of new TKIs continues to grow, it is expected that clinicians will be facing the challenge of early detection and 10 management of these side effects while balancing the risk-benefit ratios of continuing with life-saving cancer therapy medications. This review will present the current knowledge related to incidence and proposed mechanisms of cardiovascular side effects of TKIs and also discuss treatment recommendations when available Expert opinion: We will present and discuss available data and suggest recommendations related to patient monitoring and early identification of TKIs related cardiovascular toxities.",
keywords = "Biomarkers, Cardiomyopathy, Cardiovascular toxicity, Hypertension, Thrombosis, Tyrosine kinase inhibitors",
author = "Elie Mouhayar and Durand, {Jean Bernard} and Jorge Cortes",
year = "2013",
month = "9",
day = "1",
doi = "10.1517/14740338.2013.788642",
language = "English (US)",
volume = "12",
pages = "687--696",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Cardiovascular toxicity of tyrosine kinase inhibitors

AU - Mouhayar, Elie

AU - Durand, Jean Bernard

AU - Cortes, Jorge

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Introduction: Small-molecule tyrosine kinase inhibitors (TKIs) have revolutionized the management of many malignancies. However, they also have been shown to be associated with a certain degree of cardiovascular side effects that are often reversible. Areas covered: As the number of new TKIs continues to grow, it is expected that clinicians will be facing the challenge of early detection and 10 management of these side effects while balancing the risk-benefit ratios of continuing with life-saving cancer therapy medications. This review will present the current knowledge related to incidence and proposed mechanisms of cardiovascular side effects of TKIs and also discuss treatment recommendations when available Expert opinion: We will present and discuss available data and suggest recommendations related to patient monitoring and early identification of TKIs related cardiovascular toxities.

AB - Introduction: Small-molecule tyrosine kinase inhibitors (TKIs) have revolutionized the management of many malignancies. However, they also have been shown to be associated with a certain degree of cardiovascular side effects that are often reversible. Areas covered: As the number of new TKIs continues to grow, it is expected that clinicians will be facing the challenge of early detection and 10 management of these side effects while balancing the risk-benefit ratios of continuing with life-saving cancer therapy medications. This review will present the current knowledge related to incidence and proposed mechanisms of cardiovascular side effects of TKIs and also discuss treatment recommendations when available Expert opinion: We will present and discuss available data and suggest recommendations related to patient monitoring and early identification of TKIs related cardiovascular toxities.

KW - Biomarkers

KW - Cardiomyopathy

KW - Cardiovascular toxicity

KW - Hypertension

KW - Thrombosis

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84883021976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883021976&partnerID=8YFLogxK

U2 - 10.1517/14740338.2013.788642

DO - 10.1517/14740338.2013.788642

M3 - Review article

C2 - 23560546

AN - SCOPUS:84883021976

VL - 12

SP - 687

EP - 696

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 5

ER -